Timing note: The supplied event date is July 31, 2026, which is today, rather than tomorrow. This preview is framed for Church & Dwight’s 2Q26 earnings call on July 31, 2026.
Church & Dwight enters 2Q with a relatively well-defined near-term setup: management explicitly guided to ~3% organic sales growth, ~1% reported-sales decline, approximately 50 bps of adjusted gross-margin expansion, and adjusted EPS of $0.88. The key issue is therefore less whether the company reaches the EPS number and more whether its volume, distribution, innovation, and cost-mitigation trends support the company’s confidence in 3–4% full-year organic growth and 5–8% adjusted-EPS growth.
The company delivered a high-quality 1Q beat—5.0% organic sales growth, driven by 5.3% volume, and 130 bps of adjusted gross-margin expansion—but management identified about 2 points of temporary benefit from easier retailer-inventory comparisons. Thus, a deceleration toward the guided 3% organic-growth rate in 2Q would be consistent with the stated plan rather than necessarily a deterioration in demand.
The central bull case remains that CHD’s concentrated portfolio of strong household and personal-care brands—especially ARM & HAMMER, THERABREATH, HERO, and Touchland—can continue taking share through innovation and distribution gains, while productivity offsets cost pressure. The central risk is that the cost backdrop, weak pricing/mix, and elevated first-half investment spending leave little room for error in a quarter already planned to show lower year-over-year EPS.
| Metric | Company 2Q26 outlook | Investor read-through |
|---|---|---|
| Reported sales growth | ~(1%) | Entirely attributed to 2025 portfolio actions/divestitures. |
| Organic sales growth | ~3% | The most important operating KPI; should be volume-led. |
| Gross-margin change | ~+50 bps | Lower than 1Q’s +130 bps due to transportation-cost pressure ahead of mitigation actions. |
| Adjusted EPS | $0.88 | Down from $0.94 in 2Q25, reflecting higher marketing and SG&A despite margin expansion. |
| Full-year organic sales | +3% to +4% | Reiteration would preserve the underlying growth narrative. |
| Full-year adjusted EPS | +5% to +8% | Management expects the earnings-growth weighting to shift to the second half. |
For context, 2Q25 reported sales were $1.506 billion and adjusted EPS was $0.94. Applying management’s guided 1% reported-sales decline suggests an approximate 2Q26 revenue base near $1.49 billion, though portfolio changes, FX, and acquisition effects make the organic-sales metric more informative than that simple comparison.
In 1Q, CHD’s underlying consumer indicators were strong:
The 1Q call also highlighted unusually strong distribution momentum: management said CHD ranked first across CPG in total distribution points gained year over year, estimating a roughly 7% average 13-week TDP lift and a more recent 10–11% lift as retailer resets took effect. That is potentially important for 2Q and the second half because distribution gains are typically realized with a lag after resets.
Management was transparent that roughly 2 percentage points of 1Q’s 5% organic growth related to a favorable comparison with retailer inventory reductions in 1Q25. That implies the underlying run rate was closer to 3%, which is consistent with 2Q guidance.
Accordingly, a 2Q organic-sales result around 3%—particularly if supported by positive volume and market-share gains—would support rather than undermine the full-year framework. Conversely, a sub-3% result would raise questions about whether category growth, distribution gains, or innovation are translating to shipments as expected.
CHD’s 2Q margin setup is less favorable than 1Q’s:
Importantly, management expects higher marketing and SG&A in 2Q to more than offset gross-margin gains. Marketing should trend toward the company’s roughly 11% of sales evergreen target, while SG&A remains pressured in the first half by Touchland amortization and operating costs, growth investments, e-commerce, and international expansion.
This makes the quality of a potential EPS beat important. A beat generated by stronger sales volume and gross margin would be more constructive than one driven principally by tax or timing benefits.
A pressured consumer backdrop can favor CHD’s value-oriented household offerings. Management specifically noted that the value segment in laundry has been growing, while ARM & HAMMER laundry reached record share levels despite lower promotional activity than competitors.
Watch for:
THERABREATH remains one of CHD’s most important growth assets. In 1Q, the brand posted record share gains in mouthwash, reaching 24.1% share and holding the No. 2 position in the category. The new toothpaste line is an additional category-expansion opportunity.
Watch for:
HERO continued to outgrow its category in 1Q, supported by distribution, marketing activations, and the Mighty Shield innovation. Management had planned a national mid-year launch for HERO facial cleansers, making 2Q commentary on retailer placement, launch timing, and early reception relevant.
Watch for:
Touchland consumption grew low double digits in 1Q on management’s all-in measure, though tracked-channel data appeared weaker because of difficult comparisons with prior holiday multipack activity and launch timing. Management still expected double-digit full-year Touchland growth, supported by low household penetration, advertising, collaborations, and back-half activations.
Watch for:
Management maintained a full-year view of roughly 7% organic growth internationally, though it cited softer Middle East sales. The new ERP system went live in April, so the absence of customer-service, fulfillment, or operational disruptions would be a quiet but important positive.
CHD closed at $97.70 on July 30, versus $96.02 on May 1, the day of its 1Q release. The shares had traded as high as $99.93 on July 28, leaving the stock modestly below its recent pre-report peak. That suggests investors are not positioned for an obvious collapse in fundamentals, but the valuation of a defensive branded-consumer company still leaves sensitivity to any reduction in the back-half earnings outlook.
A favorable report would likely include:
A negative reaction would be more likely if CHD reports:
CHD’s 2Q26 report is primarily a validation quarter. Management has already set a modest EPS bar and a normalized 3% organic-sales target, while explicitly telling investors that earnings growth should accelerate in the second half. Therefore, the most valuable evidence will be whether volume-led growth, share gains, new-product execution, and productivity are sufficiently durable to make that second-half acceleration credible.
A 3% organic-growth result with healthy volume, intact gross-margin recovery, and reaffirmed full-year guidance would be consistent with CHD’s investment case. The higher bar is evidence that the large distribution gains and innovation pipeline can push growth above guidance without forcing additional promotional or pricing concessions.